Medical and Biological Laboratories Co., Ltd. (MBL), announced that MBL has concluded the license agreement with China National Biotec Group Co., Ltd. (CNBG) of a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM) to comprehensively license fully human monoclonal antibodies generated by MBL for four (4) infectious diseases treatment. Under this license agreement, MBL confirms the development plan implemented by CNBG and its progress, and receives a license fee including running royalties as consideration for this license. CNBG acquires the exclusive license to develop, manufacture, and sell those antibodies and to use related technical know-hows in China and the other Asian regions (excluding Japan), and begin development in China. The fully human monoclonal antibodies were generated by using MBL's basic technology of the SPYMEG* or the phage display technology. The antibodies are expected to help in treating and preventing pandemic infections including Influenza because of their broadly neutralizing activity.